- Home
- WKSP vs CTXR Comparison
WKSP vs CTXR Comparison
Compare WKSP & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- CTXR
- Stock Information
- Founded
- WKSP 2003
- CTXR 2007
- Country
- WKSP United States
- CTXR United States
- Employees
- WKSP N/A
- CTXR N/A
- Industry
- WKSP Auto Parts:O.E.M.
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- CTXR Health Care
- Exchange
- WKSP Nasdaq
- CTXR Nasdaq
- Market Cap
- WKSP 27.2M
- CTXR 28.4M
- IPO Year
- WKSP N/A
- CTXR N/A
- Fundamental
- Price
- WKSP $0.82
- CTXR $3.30
- Analyst Decision
- WKSP Strong Buy
- CTXR Strong Buy
- Analyst Count
- WKSP 1
- CTXR 2
- Target Price
- WKSP $2.00
- CTXR $54.50
- AVG Volume (30 Days)
- WKSP 1.6M
- CTXR 185.5K
- Earning Date
- WKSP 11-13-2024
- CTXR 02-12-2025
- Dividend Yield
- WKSP N/A
- CTXR N/A
- EPS Growth
- WKSP N/A
- CTXR N/A
- EPS
- WKSP N/A
- CTXR N/A
- Revenue
- WKSP $6,395,908.00
- CTXR N/A
- Revenue This Year
- WKSP $424.11
- CTXR N/A
- Revenue Next Year
- WKSP $260.82
- CTXR $216.25
- P/E Ratio
- WKSP N/A
- CTXR N/A
- Revenue Growth
- WKSP 776.97
- CTXR N/A
- 52 Week Low
- WKSP $0.36
- CTXR $2.44
- 52 Week High
- WKSP $1.54
- CTXR $26.75
- Technical
- Relative Strength Index (RSI)
- WKSP 46.71
- CTXR 41.54
- Support Level
- WKSP $0.79
- CTXR $3.70
- Resistance Level
- WKSP $0.88
- CTXR $4.43
- Average True Range (ATR)
- WKSP 0.11
- CTXR 0.54
- MACD
- WKSP -0.02
- CTXR 0.06
- Stochastic Oscillator
- WKSP 15.33
- CTXR 6.03
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.